Clinical Trials

Sponsor: Immunogen, Inc.

Sponsor Study ID: IMGN853

Study Title: Multicenter, Open-Label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate Receptor-Alpha Positive, Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Following 1 Prior Line of Platinum-Based Chemotherapy

NCT Number: NCT05456685

Phase: II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Corpus Uteri, Ovary, Other Female Genital, Cervix Uteri

Study Objectives: This Phase 2 study is designed to evaluate the efficacy and safety of MIRV in combination with carboplatin followed by MIRV continuation in FRα-positive patients with recurrent platinum-sensitive ovarian cancer (PSOC) following 1 prior line of platinum-based chemotherapy. Upon completion of carboplatin plus MIRV combination chemotherapy (6 cycles), patients without progressive disease will continue on single-agent MIRV. Patients must have confirmation of FRα positivity by the Ventana FOLR1 Assay.

---

Study Documents    
(MUSC NetID required for document access)